News

Researchers from the European University and the Sergey Berezin Medical Institute (MIBS) have calculated the effectiveness of Russian vaccines against lung damage during COVID-19 waves caused by  the Delta and Omicron strains. The effectiveness of two doses of Sputnik V was 56%. The effectiveness of three doses was 71%.  EpiVacCorona was not shown to be effective. 

Researchers from the European University at St. Petersburg and the Medical Institute named after Berezin Sergey (MIBS) calculated the effectiveness of Russian vaccines against symptomatic coronavirus infection during an outbreak caused by the delta variant. "Sputnik V" protects against the delta variant. Тhe effectiveness of the vaccine was 58%. In reality, the efficacy is even higher, since this calculated figure is influenced by the number of people who recovered but were not included in the data.

According to the results of the new stage of a serological survey, more than 80% of adults in St. Petersburg have antibodies to SARS-CoV-2. Repeat infections (confirmed by PCR tests) are relatively rare events-under 3%. In order for the active phase of the epidemic to end, as many citizens as possible must have immune protection.

The journal Science of the American Association for the Advancement of Science published an article about an independent study of the effectiveness of vaccination, which was conducted by scientists from the European University, the Medical Institute named after Sergey Berezin, the First honey in St. Petersburg and the Tarus Hospital.

Vaccinated residents of St. Petersburg with symptomatic COVID-19 are almost 5 times less likely to have severe disease. Vaccine effectiveness against hospitalization was 81% for fully vaccinated individuals.

Now Covid-19 cases are rising and the government is trying to convince hesitant residents to get a vaccine.

The July 1 webinar on COVID-19 vaccination “Hey, are you vaccinated?” featuring professors from Skoltech, the European University in Saint Petersburg and New Economic School attracted over a hundred pressing questions on SARS-CoV-2 and the vaccines against it.